Cargando…

Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine

BACKGROUND: Hepatitis B vaccine adjuvant, alum, is generally used for vaccination although it does not stimulate Th1 immunity and 10% of the population has low or no antibody response. Efforts have been continued to find more efficient vaccine adjuvants for better antibody response as well as stimul...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiancheng, He, Peng, Hu, Zhongyu, Wang, Xingtai, Liang, Zhenglun
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3050826/
https://www.ncbi.nlm.nih.gov/pubmed/21342531
http://dx.doi.org/10.1186/1743-422X-8-78
_version_ 1782199400492171264
author Zhang, Xiancheng
He, Peng
Hu, Zhongyu
Wang, Xingtai
Liang, Zhenglun
author_facet Zhang, Xiancheng
He, Peng
Hu, Zhongyu
Wang, Xingtai
Liang, Zhenglun
author_sort Zhang, Xiancheng
collection PubMed
description BACKGROUND: Hepatitis B vaccine adjuvant, alum, is generally used for vaccination although it does not stimulate Th1 immunity and 10% of the population has low or no antibody response. Efforts have been continued to find more efficient vaccine adjuvants for better antibody response as well as stimulation of Th1 immunity. METHODS: CpG DNA was used as an adjuvant for recombinant HBsAg to immunize 6- to 8-week-old female BALB/c mice with or without alum for different dosages. The production of HBsAb, CD80 and CD86 from dendritic cells, and cytokines IL-10, IL12, etc., were analyzed and compared for the performance of immunization. RESULTS: 5-20 μg CpG DNA had the best co-stimulation effect of HBsAb serum conversion for mice vaccinated with recombinant expressed HBsAg. The mice vaccinated with recombinant 20 μg CpG DNA and regular vaccine (containing alum adjuvant) had the highest concentration of antibody production. IL-12b, IL-12a and IL10 mRNA reached to the peak level between 3 and 6 hours after the CpG DNA induction in splenocytes. The expression levels of CD80 and CD86 leucocyte surface molecules were increased with 20 μg CpG DNA alone or with 20 μg CpG DNA and 4 μg HBsAg. CONCLUSIONS: Our results confirmed the adjuvant effect of CpG DNA for HBsAg in the mouse model. The increase of IL10 and IL12 production suggested the involvement of Th1 cell activation. The activation of CD80 and CD86 molecules by CpG-ODN might be part of the mechanism of T/B cells coordination and the enhancement of recombinant HBsAg induced immune response.
format Text
id pubmed-3050826
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30508262011-03-09 Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine Zhang, Xiancheng He, Peng Hu, Zhongyu Wang, Xingtai Liang, Zhenglun Virol J Research BACKGROUND: Hepatitis B vaccine adjuvant, alum, is generally used for vaccination although it does not stimulate Th1 immunity and 10% of the population has low or no antibody response. Efforts have been continued to find more efficient vaccine adjuvants for better antibody response as well as stimulation of Th1 immunity. METHODS: CpG DNA was used as an adjuvant for recombinant HBsAg to immunize 6- to 8-week-old female BALB/c mice with or without alum for different dosages. The production of HBsAb, CD80 and CD86 from dendritic cells, and cytokines IL-10, IL12, etc., were analyzed and compared for the performance of immunization. RESULTS: 5-20 μg CpG DNA had the best co-stimulation effect of HBsAb serum conversion for mice vaccinated with recombinant expressed HBsAg. The mice vaccinated with recombinant 20 μg CpG DNA and regular vaccine (containing alum adjuvant) had the highest concentration of antibody production. IL-12b, IL-12a and IL10 mRNA reached to the peak level between 3 and 6 hours after the CpG DNA induction in splenocytes. The expression levels of CD80 and CD86 leucocyte surface molecules were increased with 20 μg CpG DNA alone or with 20 μg CpG DNA and 4 μg HBsAg. CONCLUSIONS: Our results confirmed the adjuvant effect of CpG DNA for HBsAg in the mouse model. The increase of IL10 and IL12 production suggested the involvement of Th1 cell activation. The activation of CD80 and CD86 molecules by CpG-ODN might be part of the mechanism of T/B cells coordination and the enhancement of recombinant HBsAg induced immune response. BioMed Central 2011-02-23 /pmc/articles/PMC3050826/ /pubmed/21342531 http://dx.doi.org/10.1186/1743-422X-8-78 Text en Copyright ©2011 Zhang et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Zhang, Xiancheng
He, Peng
Hu, Zhongyu
Wang, Xingtai
Liang, Zhenglun
Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine
title Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine
title_full Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine
title_fullStr Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine
title_full_unstemmed Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine
title_short Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine
title_sort enhanced specific immune responses by cpg dna in mice immunized with recombinant hepatitis b surface antigen and hb vaccine
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3050826/
https://www.ncbi.nlm.nih.gov/pubmed/21342531
http://dx.doi.org/10.1186/1743-422X-8-78
work_keys_str_mv AT zhangxiancheng enhancedspecificimmuneresponsesbycpgdnainmiceimmunizedwithrecombinanthepatitisbsurfaceantigenandhbvaccine
AT hepeng enhancedspecificimmuneresponsesbycpgdnainmiceimmunizedwithrecombinanthepatitisbsurfaceantigenandhbvaccine
AT huzhongyu enhancedspecificimmuneresponsesbycpgdnainmiceimmunizedwithrecombinanthepatitisbsurfaceantigenandhbvaccine
AT wangxingtai enhancedspecificimmuneresponsesbycpgdnainmiceimmunizedwithrecombinanthepatitisbsurfaceantigenandhbvaccine
AT liangzhenglun enhancedspecificimmuneresponsesbycpgdnainmiceimmunizedwithrecombinanthepatitisbsurfaceantigenandhbvaccine